Jim Tananbaum

Founder & CEO
Foresite Capital

Jim Tananbaum is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has approximately $3.5 billion in assets under management. Jim assembles the people, ideas and money needed to launch products that save lives and improve healthcare. He is always looking for visionary entrepreneurs with insights into therapeutics, devices, diagnostics or services that could, with the right support, change the world.

Jim has been a lead financier and thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics, Amerigroup (NASDAQ: ANTM), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim co-founded and initially ran GelTex Pharmaceuticals (NASDAQ: GENZ) and Theravance (NASD: TBPH and INVA). Jim’s investment experience includes being a co-founder of Prospect Ventures and earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice. Jim has been named to Forbes’ Midas List of Top Tech Investors in four consecutive years from 2015 to 2018. His intent has been to place Foresite Capital, its resources and networks at the frontier of this data-driven revolution, and to help build transformative healthcare companies that will significantly improve the quality and effectiveness of the entire U.S. healthcare system.
Jim received his MD and MBA from Harvard, and a Master’s degree from MIT. He graduated with degrees in Applied Math and Electrical Engineering/Computer Science from Yale College.